Business & FinanceDealsHealth

MoonLake Immunotherapeutics explores sale

14 July 2023, 5:43 pm 1 minute

MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.

Market Impact

MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday, giving the company a market value of $3.3 billion.

Article Tags

Topics of Interest: Business & FinanceDealsHealth

Type: Reuters Best

Sectors: Business & FinancePharmaceuticals & Healthcare

Regions: Europe

Countries: Switzerland

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Share this article

Work Email Address *

Country *

I'd like to receive communications about Reuters resources, events, products, or services.

(Please note you can manage and update your preferences at any time.) By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.

By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field

Work Email Address *

Country *

More of Reuters Best

Abu Dhabi’s largest Islamic bank in talks to buy $1.1 bln stake in Indonesian lender

MoonLake Immunotherapeutics explores sale

Market Impact

More of Reuters Best

Abu Dhabi’s largest Islamic bank in talks to buy $1.1 bln stake in Indonesian lender

Billing software firm Zuora explores sale after takeover interest

Vietnam mounts ‘unprecedented’ $24 billion rescue for bank engulfed in giant fraud

Lockheed wins US missile defense contract worth $17 bln